{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:38:35Z","timestamp":1793191115048,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,11,18]],"date-time":"2014-11-18T00:00:00Z","timestamp":1416268800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2466-14-178","type":"journal-article","created":{"date-parts":[[2014,11,17]],"date-time":"2014-11-17T23:01:20Z","timestamp":1416265280000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":123,"title":["Efficacy and safety of aclidinium bromide\/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study"],"prefix":"10.1186","volume":"14","author":[{"given":"Dave","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Korn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Molins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Caracta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther Garcia","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Leselbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,18]]},"reference":[{"key":"628_CR1","volume-title":"Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease","author":"Global Initiative for Chronic Obstructive Lung Disease","year":"2014","unstructured":"Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2014, \n                    http:\/\/www.goldcopd.org\/uploads\/users\/files\/GOLD_Report_2013_Feb20.pdf\n                    \n                  ,"},{"key":"628_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1476-5381.2011.01216.x","volume":"163","author":"M Cazzola","year":"2011","unstructured":"Cazzola M, Calzetta L, Matera MG: beta(2) -adrenoceptor agonists: current and future direction. Br J Pharmacol. 2011, 163: 4-17. 10.1111\/j.1476-5381.2011.01216.x.","journal-title":"Br J Pharmacol"},{"key":"628_CR3","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1124\/pr.111.004580","volume":"64","author":"M Cazzola","year":"2012","unstructured":"Cazzola M, Page CP, Calzetta L, Matera MG: Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012, 64: 450-504. 10.1124\/pr.111.004580.","journal-title":"Pharmacol Rev"},{"key":"628_CR4","volume-title":"IMS Data 5\/2011-4\/2012","author":"IMS Health LS","year":"2012","unstructured":"IMS Health LS: IMS Data 5\/2011-4\/2012. 2012, Danbury, CT, US: IMS Health Incorporated"},{"key":"628_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1465-9921-14-49","volume":"14","author":"DP Tashkin","year":"2013","unstructured":"Tashkin DP, Ferguson GT: Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013, 14: 49-10.1186\/1465-9921-14-49.","journal-title":"Respir Res"},{"key":"628_CR6","first-page":"108","volume":"8","author":"M Rudolf","year":"2012","unstructured":"Rudolf M, Tashkin DP: Bronchodilators - future role in the management of chronic obstructive pulmonary disease. Eur Respir Dis. 2012, 8: 108-115.","journal-title":"Eur Respir Dis"},{"key":"628_CR7","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1517\/14656566.2013.776539","volume":"14","author":"M Cazzola","year":"2013","unstructured":"Cazzola M, Rogliani P, Matera MG: Aclidinium bromide\/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2013, 14: 775-781. 10.1517\/14656566.2013.776539.","journal-title":"Expert Opin Pharmacother"},{"key":"628_CR8","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1185\/03007990903103006","volume":"25","author":"MR Partridge","year":"2009","unstructured":"Partridge MR, Karlsson N, Small IR: Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin. 2009, 25: 2043-2048. 10.1185\/03007990903103006.","journal-title":"Curr Med Res Opin"},{"key":"628_CR9","volume-title":"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease","author":"Global Initiative for Chronic Obstructive Lung Disease","year":"2010","unstructured":"Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2010, \n                    http:\/\/www.goldcopd.org\/Guidelines\/guideline-2010-gold-report.html\n                    \n                  ,"},{"key":"628_CR10","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/j.1524-4733.2010.00772.x","volume":"13","author":"NK Leidy","year":"2010","unstructured":"Leidy NK, Wilcox TK, Jones PW, Murray L, Winnette R, Howard K, Petrillo J, Powers J, Sethi S: Development of the EXAcerbations of Chronic obstructive pulmonary disease Tool (EXACT): a patient-reported outcome (PRO) measure. Value Health. 2010, 13: 965-975. 10.1111\/j.1524-4733.2010.00772.x.","journal-title":"Value Health"},{"key":"628_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1164\/rccm.201005-0762OC","volume":"183","author":"NK Leidy","year":"2011","unstructured":"Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S: Standardizing measurement of chronic obstructive pulmonary disease exacerbations: reliability and validity of a patient-reported diary. Am J Respir Crit Care Med. 2011, 183: 323-329. 10.1164\/rccm.201005-0762OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"628_CR12","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3109\/15412555.2013.795423","volume":"10","author":"NK Leidy","year":"2013","unstructured":"Leidy NK, Murray LT: Patient-reported outcome (PRO) measures for clinical trials of COPD: the EXACT and E-RS. COPD. 2013, 10: 393-398. 10.3109\/15412555.2013.795423.","journal-title":"COPD"},{"key":"628_CR13","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1513\/AnnalsATS.201309-305OC","volume":"11","author":"NK Leidy","year":"2014","unstructured":"Leidy NK, Murray LT, Jones P, Sethi S: Performance of the EXAcerbations of Chronic pulmonary disease Tool patient-reported outcome measure in three clinical trials of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014, 11: 316-325. 10.1513\/AnnalsATS.201309-305OC.","journal-title":"Ann Am Thorac Soc"},{"key":"628_CR14","unstructured":"European Medicines Agency: Guideline on Clinical Development of Fixed Combination Medicinal Products (CHMP\/EWP\/240\/95) Rev.1. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003686.pdf\n                    \n                  ,"},{"key":"628_CR15","unstructured":"US Food and Drug Administration: Code of Federal Regulations. Title 21. Section 300.50. Fixed-Combination Prescription Drugs for Humans. \n                    http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfCFR\/CFRSearch.cfm?fr=300.50\n                    \n                  ,"},{"key":"628_CR16","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1053\/rmed.2001.1161","volume":"95","author":"D Benhamou","year":"2001","unstructured":"Benhamou D, Cuvelier A, Muir JF, Leclerc V, Le Gros V, Kottakis J, Bourdeix I: Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). Respir Med. 2001, 95: 817-821. 10.1053\/rmed.2001.1161.","journal-title":"Respir Med"},{"key":"628_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/1465-9921-11-149","volume":"11","author":"DP Tashkin","year":"2010","unstructured":"Tashkin DP, Fabbri LM: Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res. 2010, 11: 149-10.1186\/1465-9921-11-149.","journal-title":"Respir Res"},{"key":"628_CR18","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3109\/15412555.2012.661492","volume":"9","author":"EM Kerwin","year":"2012","unstructured":"Kerwin EM, D\u2019Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF, ACCORD I study investigators: Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012, 9: 90-101. 10.3109\/15412555.2012.661492.","journal-title":"COPD"},{"key":"628_CR19","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1183\/09031936.00225511","volume":"40","author":"PW Jones","year":"2012","unstructured":"Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, Segarra R, Caracta C, Garcia Gil E: Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012, 40: 830-836. 10.1183\/09031936.00225511.","journal-title":"Eur Respir J"},{"key":"628_CR20","volume-title":"Dose-Finding Study for Tiotropium and Olodaterol When Administered in Combination via the Respimat\u00ae Inhaler in Patients with COPD","author":"R Aalbers","year":"2012","unstructured":"Aalbers R, Maleki-Yazdi MR, Hamilton A, Waitere-Wijker S, Pivovarova A, Schmidt O, Bjermer L: Dose-Finding Study for Tiotropium and Olodaterol When Administered in Combination via the Respimat\u00ae Inhaler in Patients with COPD. 2012, Vienna, Austria: Poster presented at the European Respiratory Society Annual Congress"},{"key":"628_CR21","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1183\/09031936.00200212","volume":"42","author":"ED Bateman","year":"2013","unstructured":"Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, Banerji D: Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013, 42: 1484-1494. 10.1183\/09031936.00200212.","journal-title":"Eur Respir J"},{"key":"628_CR22","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.rmed.2013.06.001","volume":"107","author":"JF Donohue","year":"2013","unstructured":"Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A: Efficacy and safety of once-daily umeclidinium\/vilanterol 62.5\/25 mcg in COPD. Respir Med. 2013, 107: 1538-1546. 10.1016\/j.rmed.2013.06.001.","journal-title":"Respir Med"},{"key":"628_CR23","first-page":"1014s","volume":"36","author":"F Maltais","year":"2010","unstructured":"Maltais F, Beck E, Webster D, Maleki-Yazdi MR, Seibt J-V, Arnoux A, Hamilton A: Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients [abstract]. Eur Respir J. 2010, 36: 1014s-","journal-title":"Eur Respir J"},{"key":"628_CR24","first-page":"A6435","volume":"183","author":"C Reisner","year":"2011","unstructured":"Reisner C, Fogarty C, Spangenthal S, Dunn L, Kerwin EM, Quinn D, Seale JP, Thomas M, St Rose E, Orevillo C: Novel combination of glycopyrrolate and formoterol MDI (GFF-MDI) provides superior bronchodilation compared to its components administered alone, tiotropium DPI, and formoterol DPI in a randomized, double-blind, placebo-controlled Phase 2b study in patients with COPD [abstract]. Am J Resp Crit Care Med. 2011, 183: A6435-","journal-title":"Am J Resp Crit Care Med"},{"key":"628_CR25","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1164\/rccm.201310-1863PP","volume":"189","author":"PW Jones","year":"2014","unstructured":"Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA: Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014, 189: 250-255. 10.1164\/rccm.201310-1863PP.","journal-title":"Am J Respir Crit Care Med"},{"key":"628_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1081\/COPD-200053377","volume":"2","author":"JF Donohue","year":"2005","unstructured":"Donohue JF: Minimal clinically important differences in COPD lung function. COPD. 2005, 2: 111-124. 10.1081\/COPD-200053377.","journal-title":"COPD"},{"key":"628_CR27","doi-asserted-by":"publisher","first-page":"e15591","DOI":"10.1371\/journal.pone.0015591","volume":"5","author":"TJ Kaptchuk","year":"2010","unstructured":"Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, Singer JP, Kowalczykowski M, Miller FG, Kirsch I, Lembo AJ: Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One. 2010, 5: e15591-10.1371\/journal.pone.0015591.","journal-title":"PLoS One"},{"key":"628_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1465-9921-12-40","volume":"12","author":"M Westwood","year":"2011","unstructured":"Westwood M, Bourbeau J, Jones PW, Cerulli A, Capkun-Niggli G, Worthy G: Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res. 2011, 12: 40-10.1186\/1465-9921-12-40.","journal-title":"Respir Res"},{"key":"628_CR29","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1378\/chest.12-1277","volume":"143","author":"KF Rabe","year":"2013","unstructured":"Rabe KF, Fabbri LM, Vogelmeier C, Kogler H, Schmidt H, Beeh KM, Glaab T: Seasonal distribution of COPD exacerbations in the prevention of exacerbations with tiotropium in COPD trial. Chest. 2013, 143: 711-719.","journal-title":"Chest"},{"key":"628_CR30","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1183\/09031936.00051110","volume":"37","author":"R Kessler","year":"2011","unstructured":"Kessler R, Partridge MR, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D, Ostinelli J: Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011, 37: 264-272. 10.1183\/09031936.00051110.","journal-title":"Eur Respir J"},{"key":"628_CR31","first-page":"CD010177","volume":"10","author":"KM Kew","year":"2013","unstructured":"Kew KM, Mavergames C, Walters JA: Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013, 10: CD010177-","journal-title":"Cochrane Database Syst Rev"},{"key":"628_CR32","doi-asserted-by":"publisher","first-page":"460","DOI":"10.5414\/CPP47460","volume":"47","author":"JM Jansat","year":"2009","unstructured":"Jansat JM, Lamarca R, Garcia Gil E, Ferrer P: Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int J Clin Pharmacol Ther. 2009, 47: 460-468. 10.5414\/CPP47460.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"628_CR33","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ejps.2010.01.004","volume":"39","author":"S Sentellas","year":"2010","unstructured":"Sentellas S, Ramos I, Albert\u00ed J, Salv\u00e0 M, Ant\u00f3n F, Miralpeix M, Beleta J, Gavald\u00e0 A: Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci. 2010, 39: 283-290. 10.1016\/j.ejps.2010.01.004.","journal-title":"Eur J Pharm Sci"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2466-14-178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2466-14-178\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2466-14-178","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2466-14-178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T23:16:05Z","timestamp":1548198965000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/1471-2466-14-178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,18]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["628"],"URL":"https:\/\/doi.org\/10.1186\/1471-2466-14-178","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725239416.793532749","asserted-by":"object"}]},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,18]]},"assertion":[{"value":"13 June 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"178"}}